Literature DB >> 21337552

Expression of tissue levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in gastric adenocarcinoma.

Ming Zhang1, Guan-Yu Zhu, Hong-Yu Gao, Shu-Peng Zhao, Yingwei Xue.   

Abstract

BACKGROUND AND OBJECTIVES: Matrix metalloproteinases (MMPs) are one of the major classes of proteolytic enzymes involved in tumor invasion and metastasis, being inhibited by naturally occurring tissue inhibitors of metalloproteinases (TIMPs). We examined mRNA expression for MMP-2, MMP-7, MMP-9, MT1-MMP, TIMP-1, and TIMP-2 in human gastric adenocarcinoma tissues, and the correlation between their expression and clinicopathological variables.
METHODS: Gastric tissue samples from 72 patients with gastric adenocarcinoma were available for this study. To determine mRNA expression for MMP-2, MMP-7, MMP-9, MT1-MMP, TIMP-1, and TIMP-2, semiquantitative reverse transcriptase-polymerase chain reaction (RT-PCR) was carried out on tumor and normal tissues, respectively.
RESULTS: Mean MMP-2, MMP-7, MMP-9, MT1-MMP, TIMP-1, and TIMP-2 mRNA expression in the gastric adenocarcinomas was significantly higher than in the normal tissue. In terms of the invasion of the tumor, lymph node metastasis, and tumor stage of gastric adenocarcinoma, the differences in MMP-2, MMP-7, MMP-9, and MT1-MMP mRNA expression levels were significant. MMP-2, MMP-7, MMP-9, MT1-MMP, TIMP-1, and TIMP-2 mRNA expression did not differ significantly in relation to histological type of gastric adenocarcinoma.
CONCLUSION: The correlation between the increased expression of MMP-2, MMP-7, MMP-9, and MTI-MMP and clinicopathological parameters reflects a role in predicting the aggressive behavior of gastric cancer.
Copyright © 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21337552     DOI: 10.1002/jso.21824

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  22 in total

1.  Vascular Pathology as a Potential Therapeutic Target in SCI.

Authors:  Richard L Benton; Theo Hagg
Journal:  Transl Stroke Res       Date:  2011-11-29       Impact factor: 6.829

2.  Plk1 promotes the migration of human lung adenocarcinoma epithelial cells via STAT3 signaling.

Authors:  Weijuan Yan; Huijie Yu; Wei Li; Fengsheng Li; Sinian Wang; Nan Yu; Qisheng Jiang
Journal:  Oncol Lett       Date:  2018-09-14       Impact factor: 2.967

3.  Molecular targeted therapies in advanced gastric cancer: does tumor histology matter?

Authors:  Hilda Wong; Thomas Yau
Journal:  Therap Adv Gastroenterol       Date:  2013-01       Impact factor: 4.409

4.  Silencing SATB1 influences cell invasion, migration, proliferation, and drug resistance in nasopharyngeal carcinoma.

Authors:  Chun-Sheng Ye; Dong-Ni Zhou; Qing-Qing Yang; Yan-Fei Deng
Journal:  Int J Clin Exp Pathol       Date:  2014-02-15

5.  Stat3 promotes invasion of esophageal squamous cell carcinoma through up-regulation of MMP2.

Authors:  Xaioyan Xuan; Shanshan Li; Xi Lou; Xianzhao Zheng; Yunyun Li; Feng Wang; Yuan Gao; Hongyan Zhang; Hongliu He; Qingru Zeng
Journal:  Mol Biol Rep       Date:  2014-11-19       Impact factor: 2.316

6.  Filamin A regulates MMP-9 expression and suppresses prostate cancer cell migration and invasion.

Authors:  G G Sun; Y F Lu; J Zhang; W N Hu
Journal:  Tumour Biol       Date:  2014-01-05

7.  Absent expression of FLNA is correlated with poor prognosis of nasopharyngeal cancer.

Authors:  G G Sun; Y F Lu; Y J Cheng; W N Hu
Journal:  Tumour Biol       Date:  2013-11-12

Review 8.  Metastasis review: from bench to bedside.

Authors:  Ali Mohammad Alizadeh; Sadaf Shiri; Sadaf Farsinejad
Journal:  Tumour Biol       Date:  2014-08-08

9.  An antiproliferative gene FLNA regulates migration and invasion of gastric carcinoma cell in vitro and its clinical significance.

Authors:  G G Sun; S H Sheng; S W Jing; W N Hu
Journal:  Tumour Biol       Date:  2013-11-16

10.  Research and clinical applications of molecular biomarkers in gastrointestinal carcinoma (Review).

Authors:  Feng Jiao; Ziliang Jin; Lei Wang; Liwei Wang
Journal:  Biomed Rep       Date:  2013-08-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.